US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (ALLO) ニュース

ALLO

Allogene Therapeutics (ALLO)

Allogene Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALLO

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/06	21 : 30	GlobeNewswire Inc.	Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/04/26	21 : 30	GlobeNewswire Inc.	Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/04/09	21 : 30	GlobeNewswire Inc.	Allogene Therapeutics Announces Q2 Investor Conference Participation	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/03/15	05 : 05	GlobeNewswire Inc.	Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/03/12	21 : 30	GlobeNewswire Inc.	Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/03/05	22 : 30	GlobeNewswire Inc.	Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/02/28	22 : 30	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/02/16	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/02/16	22 : 30	GlobeNewswire Inc.	Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/02/01	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/01/25	07 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/01/23	06 : 11	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/01/17	06 : 05	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/01/05	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/01/05	06 : 15	GlobeNewswire Inc.	Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/01/05	06 : 05	GlobeNewswire Inc.	Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma	NASDAQ:ALLO	Allogene Therapeutics Inc
2024/01/04	06 : 05	GlobeNewswire Inc.	Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/12/21	06 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/12/20	05 : 46	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/12/19	06 : 17	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/12/10	02 : 00	GlobeNewswire Inc.	Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/12/01	22 : 30	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in December Investor Conference	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/11/04	01 : 00	GlobeNewswire Inc.	Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/11/04	01 : 00	GlobeNewswire Inc.	Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/11/03	05 : 41	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/11/03	05 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/11/03	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/11/03	05 : 02	GlobeNewswire Inc.	Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/11/02	22 : 00	GlobeNewswire Inc.	Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology	NASDAQ:ALLO	Allogene Therapeutics Inc
2023/10/30	21 : 30	GlobeNewswire Inc.	Allogene Therapeutics Announces Participation in November Investor Conferences	NASDAQ:ALLO	Allogene Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:ALLO

1 2 3 4 5 6 7 8 9 10 次へ >>

Gold vs US Dollar

Financial Select Sector

Energy Select Sector SPDR

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約